Login to Your Account

Washington Roundup

Ampligen Down, Probe Aims at Hemispherx Execs' Moves

By Randy Osborne
Staff Writer

Friday, December 21, 2012
Chronic fatigue syndrome (CFS) patients willing to take Ampligen if it's approved – and accept the risks, because it has worked for them in trials – faced off against charges of inadequately done studies with less than satisfying overall efficacy signals, during a meeting of the FDA's Arthritis Advisory Committee.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription